FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Releases Tech Modernization Plan

[ Price : $8.95]

FDA releases its long-awaited Technology Modernization Action Plan that describes short-term actions it is taking to modernize tec...

Development, Pre-Submission Meeting MAPP

[ Price : $8.95]

CDER issues a MAPP with policies and procedures for product development and pre-submission meetings with potential ANDA applicants...

FDA Guide on 505(q) Citizen Petitions

[ Price : $8.95]

FDA finalizes a guidance on drug-related citizen petitions and petitions for stay of action.

Info Collection Extension for Post-market Studies

[ Price : $8.95]

Federal Register notice: FDA seeks comments on an information collection extension for drug/biologic postmarketing studies status ...

CDRH Safer Technologies Program Introduced

[ Price : $8.95]

CDRH introduces its STeP safer technologies program.

Orphan Designation for Retinal Gene Therapy

[ Price : $8.95]

FDA grants an orphan drug designation for its novel gene therapy for treating the CEP290 mutation associated retinal disease.

Emergency Use Revoked for Luminex Zika Assay

[ Price : $8.95]

Federal Register notice: FDA revokes an emergency use authorization issued to Luminex for the xMAP MultiFLEX Zika RNA Assay.

Software Pre-certification May Mean More Surveillance: Attorney

[ Price : $8.95]

Attorney Vernessa Pollard says that medical device software pre-certification may lead to greater post-market surveillance and dat...

PhRMA Proposes Changes to Opioid Benefit/Risk Framework

[ Price : $8.95]

PhRMA recommends changes to an FDA draft guidance on a benefit/risk framework for evaluating prescription opioids.

Using Highlights in Failure-to-Warn Preemption

[ Price : $8.95]

Attorney James Beck says attorneys should argue for preemption of failure-to-warn claims that covers any informational claims that...